DrugId:  1
1. Name:  ATX-201
2. Groups:  Investigational
3. Description:  ATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinickeratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis. The Company determined that the program was not meeting their expected primary and exploratory objectives.
4. Indication:  Investigated for use/treatment in actinic keratosis.
DrugId:  2
1. Name:  Sotirimod
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in actinic keratosis and skin infections/disorders.
DrugId:  3
1. Name:  BF-200 ALA
2. Groups:  Approved, Investigational
3. Description:  BF-200 ALA is under investigation by Biofrontera which shows positive results from its Phase IIb/III trial. According to Biofrontera, BF-200 ALA was strongly and significantly superior to placebo in the treatment of actinic keratosis. 
4. Indication:  Investigated for use/treatment in actinic keratosis.
DrugId:  4
1. Name:  SL017
2. Groups:  Investigational
3. Description:  SL017 formulated as a topical gel, has been combined with a widely available light source for permanent removal of unwanted hair and for treatment of actinic keratosis
4. Indication:  Investigated for use/treatment in acne, actinic keratosis, cancer/tumors (unspecified), keratoses, and skin infections/disorders.
DrugId:  5
1. Name:  Ingenol Mebutate
2. Groups:  Approved
3. Description:  Ingenol mebutate was approved by the FDA in January 2012, and it is marketed under the name PicatoÂ®. Picato gel is indicated for the topical treatment of actinic keratosis. Before approval, ingenol mebutate was called PEP005 as an investigational drug. PEP005 is a selective small molecule activator of protein kinase C (PKC) extracted from the plant Euphorbia peplus, whose sap has been used as a traditional medicine for the treatment of skin conditions including warts and cancer. PEP005 also has potent anti-leukemic effects, inducing apoptosis in myeloid leukemia cell lines and primary AML cells at nanomolar concentrations. 
4. Indication:  For the topical treatment of actinic keratosis.
DrugId:  6
1. Name:  Pigment blue 16
2. Groups:  Investigational
3. Description:  Phthalocyanine is under investigation in clinical trial NCT00103246 (Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides).
4. Indication:  Not Available
DrugId:  7
1. Name:  Tretinoin
2. Groups:  Approved, Investigational, Nutraceutical
3. Description:  Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of vitamin A (retinol). Retinoids such as tretinoin are important regulators of cell reproduction, proliferation, and differentiation and are used to treat acne and photodamaged skin and to manage keratinization disorders such as ichthyosis and keratosis follicularis. Tretinoin also represents the class of anticancer drugs called differentiating agents and is used in the treatment of acute promyelocytic leukemia (APL).
4. Indication:  For the the induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant); For the topical treatment of acne vulgaris, flat warts and other skin conditions (psoriasis, ichthyosis congenita, icthyosis vulgaris, lamellar icthyosis, keratosis palmaris et plantaris, epidermolytic hyperkeratosis, senile comedones, senile keratosis, keratosis follicularis (Darier's disease), and basal cell carcinomas.); For palliative therapy to improve fine wrinkling, mottled hyperpigmentation, roughness associated with photodamage.
DrugId:  8
1. Name:  Silicon
2. Groups:  Approved, Investigational
3. Description:  Silicon is under investigation in clinical trial NCT00103246 (Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides).
4. Indication:  Not Available
DrugId:  9
1. Name:  Solamargine
2. Groups:  Investigational
3. Description:  Solamargine has been used in trials studying the treatment of Actinic Keratosis.
4. Indication:  Not Available
DrugId:  10
1. Name:  Aminolevulinic acid
2. Groups:  Approved
3. Description:  A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem]
4. Indication:  Aminolevulinic acid plus blue light illumination using a blue light photodynamic therapy illuminator is indicated for the treatment of minimally to moderately thick actinic keratoses of the face or scalp.
DrugId:  11
1. Name:  Adapalene
2. Groups:  Approved
3. Description:  Adapalene is a topical retinoid primarily used in the treatment of acne and is also used (off-label) to treat keratosis pilaris as well as other skin conditions. It is currently marketed by Galderma under the trade names Differin in some countries, and Adaferin in India.
4. Indication:  For the topical treatment of comedo, papular and pustular acne (acne vulgaris) of the face, chest or back.
DrugId:  12
1. Name:  Afamelanotide
2. Groups:  Approved, Investigational
3. Description:  Afamelanotide is an analog of the peptide hormone alpha-melanocyte stimulating hormone (alpha-MSH) that tends to induce skin tanning. It is being developed by the Australian company Clinuvel Pharmaceuticals (previously known as EpiTan). Afamelanotide was approved in Europe in October, 2014 for the treatment of erythropoietic protoporphyria (EPP). Clinuvel now intends to seek approval of afamelanotide in the United States.
4. Indication:  Investigated for use/treatment in actinic keratosis, keratoses, skin cell studies, and skin infections/disorders.
DrugId:  13
1. Name:  Diclofenac
2. Groups:  Approved, Vet approved
3. Description:  A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt. [PubChem]
4. Indication:  For the acute and chronic treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis.
DrugId:  14
1. Name:  Salicylic acid
2. Groups:  Approved, Investigational, Vet approved
3. Description:  A compound obtained from the bark of the white willow and wintergreen leaves, and also prepared synthetically. It has bacteriostatic, fungicidal, and keratolytic actions. Its salts, the salicylates, are used as analgesics.
4. Indication:  Key additive in many skin-care products for the treatment of acne, psoriasis, callouses, corns, keratosis pilaris and warts.
